These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 37055195)
1. Long-Term Outcomes in IgA Nephropathy. Pitcher D; Braddon F; Hendry B; Mercer A; Osmaston K; Saleem MA; Steenkamp R; Wong K; Turner AN; Wang K; Gale DP; Barratt J Clin J Am Soc Nephrol; 2023 Jun; 18(6):727-738. PubMed ID: 37055195 [TBL] [Abstract][Full Text] [Related]
2. Progression of IgA nephropathy under current therapy regimen in a Chinese population. Li X; Liu Y; Lv J; Shi S; Liu L; Chen Y; Zhang H Clin J Am Soc Nephrol; 2014 Mar; 9(3):484-9. PubMed ID: 24408121 [TBL] [Abstract][Full Text] [Related]
3. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Le W; Liang S; Hu Y; Deng K; Bao H; Zeng C; Liu Z Nephrol Dial Transplant; 2012 Apr; 27(4):1479-85. PubMed ID: 21965586 [TBL] [Abstract][Full Text] [Related]
4. Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort. Coppo R; Lofaro D; Camilla RR; Bellur S; Cattran D; Cook HT; Roberts IS; Peruzzi L; Amore A; Emma F; Fuiano L; Berg U; Topaloglu R; Bilginer Y; Gesualdo L; Polci R; Mizerska-Wasiak M; Caliskan Y; Lundberg S; Cancarini G; Geddes C; Wetzels J; Wiecek A; Durlik M; Cusinato S; Rollino C; Maggio M; Praga M; K Smerud H; Tesar V; Maixnerova D; Barratt J; Papalia T; Bonofiglio R; Mazzucco G; Giannakakis C; Soderberg M; Orhan D; Di Palma AM; Maldyk J; Ozluk Y; Sudelin B; Tardanico R; Kipgen D; Steenbergen E; Karkoszka H; Perkowska-Ptasinska A; Ferrario F; Gutierrez E; Honsova E Pediatr Nephrol; 2017 Jan; 32(1):139-150. PubMed ID: 27557557 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Rovin BH; Barratt J; Heerspink HJL; Alpers CE; Bieler S; Chae DW; Diva UA; Floege J; Gesualdo L; Inrig JK; Kohan DE; Komers R; Kooienga LA; Lafayette R; Maes B; Małecki R; Mercer A; Noronha IL; Oh SW; Peh CA; Praga M; Preciado P; Radhakrishnan J; Rheault MN; Rote WE; Tang SCW; Tesar V; Trachtman H; Trimarchi H; Tumlin JA; Wong MG; Perkovic V; Lancet; 2023 Dec; 402(10417):2077-2090. PubMed ID: 37931634 [TBL] [Abstract][Full Text] [Related]
6. Quantifying Duration of Proteinuria Remission and Association with Clinical Outcome in IgA Nephropathy. Canney M; Barbour SJ; Zheng Y; Coppo R; Zhang H; Liu ZH; Matsuzaki K; Suzuki Y; Katafuchi R; Reich HN; Cattran D; ; J Am Soc Nephrol; 2021 Feb; 32(2):436-447. PubMed ID: 33514642 [TBL] [Abstract][Full Text] [Related]
7. Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. Lv J; Zhang H; Wong MG; Jardine MJ; Hladunewich M; Jha V; Monaghan H; Zhao M; Barbour S; Reich H; Cattran D; Glassock R; Levin A; Wheeler D; Woodward M; Billot L; Chan TM; Liu ZH; Johnson DW; Cass A; Feehally J; Floege J; Remuzzi G; Wu Y; Agarwal R; Wang HY; Perkovic V; JAMA; 2017 Aug; 318(5):432-442. PubMed ID: 28763548 [TBL] [Abstract][Full Text] [Related]
8. Prognosis of IgA nephropathy patient with proteinuria remission by supportive therapy: cohort from screening failed Chinese patients in TESTING study. Guo Y; Shi S; Zhao J; Wang C; Liu Z; Fu S; Chen N; Li G; Wang L; Ni Z; Zhang H; Lai L; Lv J; Zhang H Ren Fail; 2024 Dec; 46(2):2398826. PubMed ID: 39248402 [TBL] [Abstract][Full Text] [Related]
9. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial. Li S; Li JP Trials; 2020 Jan; 21(1):31. PubMed ID: 31907076 [TBL] [Abstract][Full Text] [Related]
10. Immunosuppressive agents for treating IgA nephropathy. Natale P; Palmer SC; Ruospo M; Saglimbene VM; Craig JC; Vecchio M; Samuels JA; Molony DA; Schena FP; Strippoli GF Cochrane Database Syst Rev; 2020 Mar; 3(3):CD003965. PubMed ID: 32162319 [TBL] [Abstract][Full Text] [Related]
11. Reduction in proteinuria after immunosuppressive therapy and long-term kidney outcomes in patients with immunoglobulin A nephropathy. Kang SC; Kim HW; Chang TI; Kang EW; Lim BJ; Park JT; Yoo TH; Jeong HJ; Kang SW; Han SH Korean J Intern Med; 2021 Sep; 36(5):1169-1180. PubMed ID: 33561333 [TBL] [Abstract][Full Text] [Related]
12. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Manno C; Torres DD; Rossini M; Pesce F; Schena FP Nephrol Dial Transplant; 2009 Dec; 24(12):3694-701. PubMed ID: 19628647 [TBL] [Abstract][Full Text] [Related]
13. Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. Lv J; Wong MG; Hladunewich MA; Jha V; Hooi LS; Monaghan H; Zhao M; Barbour S; Jardine MJ; Reich HN; Cattran D; Glassock R; Levin A; Wheeler DC; Woodward M; Billot L; Stepien S; Rogers K; Chan TM; Liu ZH; Johnson DW; Cass A; Feehally J; Floege J; Remuzzi G; Wu Y; Agarwal R; Zhang H; Perkovic V; JAMA; 2022 May; 327(19):1888-1898. PubMed ID: 35579642 [TBL] [Abstract][Full Text] [Related]
14. Long-term renal outcomes of IgA nephropathy presenting with different levels of proteinuria. Ai Z; Zhou Q; Huang F; Yang Q; Yu X Clin Nephrol; 2020 Dec; 94(6):290-296. PubMed ID: 32990213 [TBL] [Abstract][Full Text] [Related]
15. Time-Varying Proteinuria and Progression of IgA Nephropathy: A Cohort Study. Tang C; Chen P; Si FL; Lv JC; Shi SF; Zhou XJ; Liu LJ; Zhang H Am J Kidney Dis; 2024 Aug; 84(2):170-178.e1. PubMed ID: 38364955 [TBL] [Abstract][Full Text] [Related]
16. Clinicopathological Characteristics and Impacts on Clinical Outcomes of Thrombotic Microangiopathy Lesions in Patients with Immunoglobulin A Nephropathy in Thailand. Puapatanakul P; Banjongjit A; Kanjanabuch T; Surintrspanont J; Iampenkhae K; Praditpornsilpa K; Eiam-Ong S; Boonpucknavig V Am J Nephrol; 2023; 54(7-8):308-318. PubMed ID: 37429271 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lafayette R; Kristensen J; Stone A; Floege J; Tesař V; Trimarchi H; Zhang H; Eren N; Paliege A; Reich HN; Rovin BH; Barratt J; Lancet; 2023 Sep; 402(10405):859-870. PubMed ID: 37591292 [TBL] [Abstract][Full Text] [Related]
18. Impact of body mass index on progression of primary immunoglobulin a nephropathy. Nagaraju SP; Rangaswamy D; Mareddy AS; Prasad S; Kaza S; Shenoy S; Saraf K; Attur RP; Parthasarathy R; Kosuru S; Mateti UV; Guddattu V; Koulmane Laxminarayana SL Saudi J Kidney Dis Transpl; 2018; 29(2):318-325. PubMed ID: 29657199 [TBL] [Abstract][Full Text] [Related]
19. Remission of Hematuria Improves Renal Survival in IgA Nephropathy. Sevillano AM; Gutiérrez E; Yuste C; Cavero T; Mérida E; Rodríguez P; García A; Morales E; Fernández C; Martínez MA; Moreno JA; Praga M J Am Soc Nephrol; 2017 Oct; 28(10):3089-3099. PubMed ID: 28592423 [TBL] [Abstract][Full Text] [Related]
20. Long-term renal survival and undetected risk factors of IgA nephropathy in Chinese children-a retrospective 1243 cases analysis from single centre experience. Wu H; Fang X; Xia Z; Gao C; Peng Y; Li X; Zhang P; Kuang Q; Wang R; Wang M J Nephrol; 2020 Dec; 33(6):1263-1273. PubMed ID: 32507961 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]